# Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

> **NCT02128100** · PHASE2 · COMPLETED · sponsor: **University of Louisville** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **DRUG:** Folfirinox
- **RADIATION:** Stereotactic Body Radiation Therapy

## Key facts

- **NCT ID:** NCT02128100
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-19
- **Primary completion:** 2021-03-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02128100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02128100, "Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02128100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*